HBM BIOVENTURES AG Form SC 13G March 21, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. ____)*

Arena Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, \$.0001 par value (Title of Class of Securities)

040047102 (CUSIP Number)

March 11, 2002 (Date of Event which Requires filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [] Rule 13d-1(b)
- [x] Rule 13d-1(c)
- [] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 040047102

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

HBM BioVentures AG

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) []

(b) []

3 SEC USE ONLY		
4 CITIZENSHIP OR PLACE OF ORGANIZATION		
Switzerland		
	5	SOLE VOTING POWER
NUMBER O	F	1,604,665
SHARES	6	SHARED VOTING POWER
BENEFICIALLY		-0-
OWNED BY EACH		SOLE DISPOSITIVE POWER
REPORTING		1,604,665
PERSON		SHARED DISPOSITIVE POWER
WITH		-0-
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
1,604,665		
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
Not Applicable.		
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9		
5.82%		
12 TYPE OF REPORTING PERSON		
СО		
2		
ITEM 1. (a)	Name of Is:	
		maceuticals, Inc.
(b)		Issuer's Principal Executive Offices:
		Ridge Drive, San Diego, CA 92121
ITEM 2. (a)	Name of Pe	rson Filing:
	HBM BioVe	
(b)	Address of	Principal Business Office or, if none, Residence:
	The follows the filing	ing is the address of the principal business office of person:
	Zugerstras	se 50

6340 Baar Switzerland

(c) Citizenship:

Switzerland

(d) Title of Class of Securities:

Common Stock, \$.0001 par value

(e) CUSIP Number:

040047102

ITEM 3. If this Statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

- ITEM 4. Ownership
 - (a) Amount Beneficially Owned: 1,604,665
 - (b) Percent of Class: 5.82%
 - (c) Number of shares as to which the person has:.
 - (i) Sole power to vote or to direct the vote 1,604,665
 - (ii) Shared power to vote or to direct the vote -0-
 - (iii) Sole power to dispose or to direct the disposition $1,604,665\,$
 - (iv) Shared power to dispose or to direct the disposition -0-

3

ITEM 5. Ownership of Five Percent or Less of a Class

Not applicable.

- ITEM 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable.
- ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

1,034,665 of the shares beneficially owned by the Reporting Person and reported herein are owned directly by International BM Biomedicine Holdings Inc. and indirectly by the Reporting Person pursuant to Rule 13d-3(d)(1)(i).

ITEM 8. Identification and Classification of Members of the Group

Not applicable.

ITEM 9. Notice of Dissolution of Group

Not applicable.

ITEM 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, ${\tt I}$ certify that the information set forth in this statement is true, complete and correct.

Date: March 21, 2002

/s/ Joachim Rudolf

By: Joachim Rudolf

Title: Chief Financial Officer

4